Genetic changes in blood cells may reveal how certain blood cancers are likely to progress years before worsening disease becomes apparent through routine blood tests, according to new research involving long-term genetic monitoring of patients.

Study Findings

The study, published in Cancer Discovery, followed 30 people with myeloproliferative neoplasms, or MPNs, a group of chronic blood cancers that develop in the bone marrow and cause abnormal production of blood cells. Researchers combined repeated DNA sequencing with nearly 8,000 blood-count results and detailed clinical histories to track how the diseases changed over time.

The research was conducted by scientists at the Wellcome Sanger Institute and collaborators at Cambridge University Hospitals. Some patients were followed for as long as 25 years, with researchers analyzing more than 450 samples to trace how populations of abnormal blood cells evolved.

Implications for Treatment

The findings suggest that the biological trajectory of some blood cancers may be detectable long before doctors can see the consequences through conventional monitoring. This could eventually contribute to a more personalized approach to monitoring blood cancer patients, allowing doctors to increase monitoring for patients whose DNA begins showing concerning changes, potentially catching progression earlier.

Original reporting: WOWO News/Talk (Fort Wayne) — read the source article.